Stockscreener 앱 받기
0.4629
3.37%
0.0151
시간 외 거래:
.46
-0.0029
-0.63%
전일 마감가:
$0.4478
열려 있는:
$0.4423
하루 거래량:
1.58M
Relative Volume:
0.74
시가총액:
$45.39M
수익:
$190.00K
순이익/손실:
$-70.03M
주가수익비율:
-0.6304
EPS:
-0.7343
순현금흐름:
$-59.30M
1주 성능:
-1.17%
1개월 성능:
-8.15%
6개월 성능:
-34.77%
1년 성능:
-90.99%
1일 변동 폭
$0.4423
$0.4972
1주일 범위
$0.44
$0.4972
52주 변동 폭
$0.395
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
명칭
Atyr Pharma Inc
전화
(858) 731-8389
주소
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.4629 | 43.47M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-15 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-09-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-09-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-09-15 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-02-18 | 개시 | Leerink Partners | Outperform |
| 2025-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-10-04 | 개시 | Wells Fargo | Overweight |
| 2024-09-05 | 개시 | Jefferies | Buy |
| 2023-07-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-10-12 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-21 | 개시 | Piper Sandler | Overweight |
| 2021-05-10 | 개시 | Laidlaw | Buy |
| 2020-08-17 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-03-04 | 개시 | ROTH Capital | Buy |
| 2020-03-02 | 개시 | Oppenheimer | Outperform |
| 2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2017-09-07 | 개시 | Piper Jaffray | Overweight |
| 2016-12-13 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2015-12-16 | 개시 | Citigroup | Neutral |
| 2015-06-01 | 개시 | Citigroup | Buy |
| 2015-06-01 | 개시 | JP Morgan | Overweight |
모두보기
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
FMR LLC Significantly Reduces Holdings in aTyr Pharma Inc - GuruFocus
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
aTyr Pharma Company Profile & Introduction - Moomoo
aTyr Pharma Granted Nasdaq Extension to Regain Compliance - The Globe and Mail
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide - simplywall.st
aTyr Pharma Received Notice of Noncompliance - TradingView
aTyr Pharma (NASDAQ: ATYR) wins second Nasdaq deadline to fix sub-$1 share price - Stock Titan
aTyr Pharma (ATYR) Faces Steep Decline as Shares Test Key Support ZoneJelly Roll Trade - The League of Women Voters of Texas
FMR LLC discloses 5.94M-share stake in ATYR (NASDAQ: ATYR) Amendment No.14 - Stock Titan
Phase 3 Efzofitimod Readout Nears: What ATYR Investors Should Watch in Pulmonary Sarcoidosis - TipRanks
aTyr Pharma (ATYR) Price Target Decreased by 37.13% to 6.48 - MSN
aTyr Pharma Refines Efzofitimod Strategy After Phase 2 Data - TipRanks
aTyr Pharma (ATYR) refocuses efzofitimod after EFZO-FIT miss with new Phase 3 sarcoidosis trial - Stock Titan
aTyr Pharma Inc stock (US53227K1025): Insider buying and price gains draw focus - AD HOC NEWS
aTYR Pharma director Paul Schimmel buys $49,630 in common stock By Investing.com - Investing.com Australia
aTYR Pharma director Paul Schimmel buys $49,630 in common stock - Investing.com
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Director at aTyr Pharma (NASDAQ: ATYR) adds 100K shares - Stock Titan
aTyr Pharma plans new phase 3 trial for pulmonary sarcoidosis drug - Investing.com Nigeria
aTyr Pharma (ATYR) Slips 1.22%, Approaching Key Support at $0.46Total Put Call - newsline.com
aTyr Pharma Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Some Relief Amid Pipeline DevelopmentBasic EPS Analysis - newsline.com
Why Is aTyr Stock Falling Today? - MSN
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings - Moomoo
aTyr Pharma stock (US53227K1025): clinical pipeline update keeps biotech in focus - AD HOC NEWS
ATyr Pharma revamps efzofitimod path with new phase III sarcoidosis trial - MSN
Freedom Capital Markets Initiates ATyr Pharma(ATYR.US) With Buy Rating, Announces Target Price $3.5 - Moomoo
ATYR Upgraded by Freedom Broker -- Price Target Raised to $3.50 - GuruFocus
ATyr Pharma Raised to Buy From Hold by Freedom Broker - Moomoo
ATyr Pharma Price Target Raised to $3.50/Share From $1.00 by Freedom Broker - Moomoo
aTyr Pharma upgraded to Buy from Hold at Freedom Broker - TipRanks
Atyr plans new global clinical trial of efzofitimod in pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma stock (US0021202025): fresh quarterly loss keeps biotech in focus - AD HOC NEWS
Wells Fargo Maintains ATyr Pharma(ATYR.US) With Hold Rating, Maintains Target Price $1 - Moomoo
Number of shareholders of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Number of shareholders of aTyr Pharma, Inc. – LS:A2PM86 - TradingView
aTyr Pharma Inc stock (US53227K1025): biotech under pressure as short interest jumps and earnings su - AD HOC NEWS
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
[10-Q] aTYR PHARMA INC Quarterly Earnings Report - Stock Titan
aTyr: Advancing Efzofitimod for Pulmonary Sarcoidosis - GuruFocus
aTyr Pharma Inc options imply 30.5% move in share price post-earnings - TipRanks
aTyr Pharma Reports Q1 2026 Results, Advances Efzofitimod Phase 3 for Pulmonary Sarcoidosis After FDA Meeting - Minichart
ATyr Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
aTyr Pharma Inc reports results for the quarter ended March 31Earnings Summary - TradingView
aTyr Pharma Announces First Quarter 2026 Results and Provides Corporate Update - The Manila Times
Atyr Pharma: Q1 Earnings Snapshot - marketscreener.com
aTyr Pharma (NASDAQ: ATYR) details Q1 2026 loss and Phase 3 plan - Stock Titan
aTyr Pharma, Inc. (ATYR) Discusses FDA Feedback and Next Steps for Efzofitimod in Pulmonary Sarcoidosis After Phase III ResultsSlideshow (NASDAQ:ATYR) 2026-05-14 - Seeking Alpha
Atyr Pharma Inc (ATYR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Atyr Pharma Inc 주식 (ATYR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Feb 04 '26 |
Sale |
0.98 |
3,745 |
3,655 |
153,553 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
2.60%
0.94%
자본화:
|
볼륨(24시간):